Abstract
BackgroundApproved anti-PD-1/PD-L1 immunotherapy has demonstrated clinical benefits for breast cancer (BC) mostly in triple-negative breast cancer (TNBC) patients. Developing effective immunotherapies for breast cancer is slow in part due to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have